PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9195148-1	1997	This study compared a new intranasal anti-allergic drug, azelastine (0.56 mg bid) with intranasal beclomethasone (0.2 mg bid) and placebo in the treatment of symptoms associated with seasonal rhinitis.	azelastine	57-67	BH3 interacting domain death agonist	Homo sapiens	77-80	
8595539-6	1996	For the azelastine 2 sprays bid group, the overall results were significant at P = .05 for the major symptom complex score and at .05 < P = .10 for the total symptom complex score versus placebo.	azelastine	8-18	BH3 interacting domain death agonist	Homo sapiens	28-31